# Suchul Jang

> Suchul Jang is a Korean-born biotech scientist and executive who leads Illimis Therapeutics USA as Chief Executive Officer from Boston. Trained at POSTECH and the University of Gothenburg, he built his career in exosome engineering at Codiak BioSciences, where he co-invented the clinical candidate exoSTING, before moving into leadership at hC Bioscience and then Illimis. He now runs the U.S. arm of a Seoul-based company advancing GAIA, a Gas6-based fusion protein platform designed to clear amyloid and other misfolded proteins from the brain through TAM receptor biology without triggering the inflammation that has complicated Alzheimer's therapies.

- **Role:** Chief Executive Officer at Illimis Therapeutics USA
- **Organizations:** Illimis Therapeutics USA, Illimis Therapeutics, hC Bioscience, Codiak BioSciences, University of Gothenburg, Pohang University of Science and Technology (POSTECH)
- **Nationality:** South Korean
- **Education:** B.S. and Ph.D., Pohang University of Science and Technology (POSTECH), Postdoctoral training (lab of Dr. Jan Lotvall), University of Gothenburg, Sweden
- **Known for:** Co-invented exoSTING, the first clinical candidate of Codiak BioSciences., Invented exosome-mimetic nanovesicles for anti-cancer drug delivery during his doctoral program., Holds more than 20 patents and has published 36 peer-reviewed articles.

## Career timeline

- **PhD** — Invented exosome-mimetic nanovesicles to deliver anti-cancer therapeutics during doctoral studies at POSTECH.
- **Postdoc** — Trained in the extracellular vesicle group of Dr. Jan Lotvall at the University of Gothenburg.
- **Codiak** — Rose from Scientist to Director of Preclinical & Biomarkers and Head of In Vivo Pharmacology at Codiak BioSciences; co-invented exoSTING.
- **hC Bioscience** — Served as Senior Director, Biology at hC Bioscience, working on tRNA-based therapeutics.
- **2024** — Joined Illimis Therapeutics as Chief of Staff to CEO Sanghoon Park.
- **2025** — Became Chief Executive Officer of Illimis Therapeutics USA, based in Boston.

## Achievements

- Co-invented exoSTING, the first clinical candidate of Codiak BioSciences.
- Invented exosome-mimetic nanovesicles for anti-cancer drug delivery during his doctoral program.
- Holds more than 20 patents and has published 36 peer-reviewed articles.
- Advanced multiple exosome programs at Codiak, including exoIL-12, exoASO-STAT6, and exoVACC.
- Leads the U.S. operations of Illimis Therapeutics following its $42M Series B and its research collaboration with Eli Lilly.

## Latest updates

- **2025-07** — Illimis closed a 58 billion KRW (about $42M) Series B to accelerate its GAIA-based CNS and immune-disease pipeline.
- **2025** — Suchul Jang moved into the CEO role at Illimis Therapeutics USA, based in Boston.

## Links

- Website: https://illimistx.com
- LinkedIn: http://www.linkedin.com/in/suchul-jang-81b6339a
- Twitter/X: https://twitter.com/Illimistx

---

Profile page: https://yespress.io/suchul-jang
Published by YesPress — https://yespress.io
Last updated: 2026-08-06